Brian V. Burke, MD, FACP, Mary M. Julius, RDN, LD, CDCES, Stephanie De Leon Ansley, MS, RD, CSSD, LD, CDCES, and Brian James, MEd, explained how this avatar-to-avatar DSMES program operates.
Jerome F. Strauss III, MD, PhD, Erik A. Richter, MD, DMSci, Karen Elkind-Hirsch, MS, PhD, and Anuja Dokras, MD, PhD, reviewed advances in the diagnosis and care of women with polycystic ovary syndrome.
Catlin Dennis, MPH, Gretchen Piatt, PhD, MPH, Christine H. Wang, PhD, and Sarah Westen, PhD, will come together to help quantify the toll the COVID-19 pandemic has taken on diabetes patients and their families.
Data support the use of telehealth and remote monitoring for patients with diabetes. Leslie A. Eiland, MD, Lindsay S. Mayberry, PhD, MS, and Irl B. Hirsch, MD, outline how to use these tools for different populations.
The symposium will include a review of treatment options for preproliferative diabetic retinopathy by Jennifer Sun, MD, MPH, and an overview of advancements in retinal neurovascular degeneration in diabetes by Patrice E. Fort, PhD, MS.
“The understanding of energy metabolism and its relation to diabetes and obesity is undergoing a revolution,” said Bruce Spiegelman, PhD, one of the researchers who will discuss emerging paradigms of uncoupled bioenergentics in metabolic disease.
Some type 1 diabetes trials that were suspended last year because of COVID-19 have resumed. Carla Greenbaum, MD, and Adriana Weinberg, MD, debated whether such studies should have restarted while the pandemic is ongoing.
Brian M. Schmidt, DPM, and Laura Shin, DPM, PhD, shared strategies used to maintain access to care and regular physical exams for patients with diabetic foot complications amid COVID-19.
Emilyn Uy Alejandro, PhD, and Rochelle N. Naylor, MD, will discuss new insight into the heterogeneity of diabetes and how it translates to patient care.
Yehuda Handelsman, MD, Tina Costacou, PhD, and Sophia Zoungas, MBBS (Hons), PhD, FRACP, will examine the dynamics of weight and cardiovascular risk in type 1 diabetes. The symposium includes a debate on drugs to prevent cardiovascular disease.